THEMIS: A Framework for Cost-Benefit Analysis of COVID-19 Non-Pharmaceutical Interventions
View ORCID ProfileDimitris Bertsimas, View ORCID ProfileMichael Lingzhi Li, View ORCID ProfileSaksham Soni
doi: https://doi.org/10.1101/2022.04.09.22273656
Dimitris Bertsimas
1Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02142
Michael Lingzhi Li
2Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139
Saksham Soni
1Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02142
Data Availability
All code and data are available online at https://github.com/COVIDAnalytics/THEMIS.
Posted April 10, 2022.
THEMIS: A Framework for Cost-Benefit Analysis of COVID-19 Non-Pharmaceutical Interventions
Dimitris Bertsimas, Michael Lingzhi Li, Saksham Soni
medRxiv 2022.04.09.22273656; doi: https://doi.org/10.1101/2022.04.09.22273656
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (201)
- Cardiovascular Medicine (2936)
- Dermatology (249)
- Emergency Medicine (439)
- Epidemiology (12741)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4580)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2914)
- Health Policy (1069)
- Hematology (388)
- HIV/AIDS (924)
- Medical Education (425)
- Medical Ethics (115)
- Nephrology (468)
- Neurology (4348)
- Nursing (236)
- Nutrition (638)
- Oncology (2268)
- Ophthalmology (645)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1196)
- Primary Care Research (496)
- Public and Global Health (6933)
- Radiology and Imaging (1527)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (487)
- Toxicology (60)
- Transplantation (210)
- Urology (180)